I follow a number of biotechs, including Gilead, concerning which you posted Vistide information. (Also have shares of Agouron, Akorn, Arris, Celgene, Neurobiological Technology, and Pharmacyclics -- am interested in Ariad, Sepracor, and Chiron.)
To find out the interests of any poster in SI, just click on the name in the post. You'll get a list of recent posts from that person.
In this uncertain market, Agouron is probably the safest buy because Viracept trials will conclude this year and FDA should consider it in the Spring. |
